Cargando…
Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment
Carboplatin (CPT) and paclitaxel (PTX) used in combination is one of the most effective treatments for ovarian cancer. However, the traditional combination methods used to co-administrate CPT and PTX showed limited clinical efficacy due to their distinct pharmacokinetics. Although much effort has be...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Royal Society of Chemistry
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450007/ https://www.ncbi.nlm.nih.gov/pubmed/28603607 http://dx.doi.org/10.1039/c7ra01100h |
_version_ | 1783239867859206144 |
---|---|
author | Zhang, Xiaoyang Liu, Yarong Kim, Yu Jeong Mac, John Zhuang, Rachel Wang, Pin |
author_facet | Zhang, Xiaoyang Liu, Yarong Kim, Yu Jeong Mac, John Zhuang, Rachel Wang, Pin |
author_sort | Zhang, Xiaoyang |
collection | PubMed |
description | Carboplatin (CPT) and paclitaxel (PTX) used in combination is one of the most effective treatments for ovarian cancer. However, the traditional combination methods used to co-administrate CPT and PTX showed limited clinical efficacy due to their distinct pharmacokinetics. Although much effort has been devoted to developing nanoparticles capable of encapsulating drugs with different lipophilicites, co-delivery of carboplatin with paclitaxel by a single nanoparticle has rarely been reported. Here, we encapsulated and delivered this drug combination to ovarian cancer cells at a controlled ratio by a previously reported crosslinked multilamellar liposome vesicle (cMLV). A 1 : 1 CPT/PTX molar ratio for cMLVs (CPT/PTX) combination treatment was found to induce the strongest anti-tumor synergism and to target ALDH+ cancer stem cells (CSC) in vitro. Moreover, we demonstrated that this co-encapsulation strategy reduced systemic cytotoxicity and resulted in a stronger anti-tumor effect when compared to free drug combinations and individual drug-loaded cMLVs in an OVCAR8 ovarian cancer xenograft mouse model. Thus, this study suggests a potentially promising combination therapy for ovarian cancer in clinical practice. |
format | Online Article Text |
id | pubmed-5450007 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Royal Society of Chemistry |
record_format | MEDLINE/PubMed |
spelling | pubmed-54500072017-06-09 Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment Zhang, Xiaoyang Liu, Yarong Kim, Yu Jeong Mac, John Zhuang, Rachel Wang, Pin RSC Adv Chemistry Carboplatin (CPT) and paclitaxel (PTX) used in combination is one of the most effective treatments for ovarian cancer. However, the traditional combination methods used to co-administrate CPT and PTX showed limited clinical efficacy due to their distinct pharmacokinetics. Although much effort has been devoted to developing nanoparticles capable of encapsulating drugs with different lipophilicites, co-delivery of carboplatin with paclitaxel by a single nanoparticle has rarely been reported. Here, we encapsulated and delivered this drug combination to ovarian cancer cells at a controlled ratio by a previously reported crosslinked multilamellar liposome vesicle (cMLV). A 1 : 1 CPT/PTX molar ratio for cMLVs (CPT/PTX) combination treatment was found to induce the strongest anti-tumor synergism and to target ALDH+ cancer stem cells (CSC) in vitro. Moreover, we demonstrated that this co-encapsulation strategy reduced systemic cytotoxicity and resulted in a stronger anti-tumor effect when compared to free drug combinations and individual drug-loaded cMLVs in an OVCAR8 ovarian cancer xenograft mouse model. Thus, this study suggests a potentially promising combination therapy for ovarian cancer in clinical practice. Royal Society of Chemistry 2017-04-03 2017-04-03 /pmc/articles/PMC5450007/ /pubmed/28603607 http://dx.doi.org/10.1039/c7ra01100h Text en This journal is © The Royal Society of Chemistry 2017 http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 Unported License (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Chemistry Zhang, Xiaoyang Liu, Yarong Kim, Yu Jeong Mac, John Zhuang, Rachel Wang, Pin Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment |
title | Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment
|
title_full | Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment
|
title_fullStr | Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment
|
title_full_unstemmed | Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment
|
title_short | Co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment
|
title_sort | co-delivery of carboplatin and paclitaxel via cross-linked multilamellar liposomes for ovarian cancer treatment |
topic | Chemistry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450007/ https://www.ncbi.nlm.nih.gov/pubmed/28603607 http://dx.doi.org/10.1039/c7ra01100h |
work_keys_str_mv | AT zhangxiaoyang codeliveryofcarboplatinandpaclitaxelviacrosslinkedmultilamellarliposomesforovariancancertreatment AT liuyarong codeliveryofcarboplatinandpaclitaxelviacrosslinkedmultilamellarliposomesforovariancancertreatment AT kimyujeong codeliveryofcarboplatinandpaclitaxelviacrosslinkedmultilamellarliposomesforovariancancertreatment AT macjohn codeliveryofcarboplatinandpaclitaxelviacrosslinkedmultilamellarliposomesforovariancancertreatment AT zhuangrachel codeliveryofcarboplatinandpaclitaxelviacrosslinkedmultilamellarliposomesforovariancancertreatment AT wangpin codeliveryofcarboplatinandpaclitaxelviacrosslinkedmultilamellarliposomesforovariancancertreatment |